Therapeutic effects of Omarigliptin

In a multicenter, double-blind, 12-week dose-ranging study, 685 subjects with type 2 diabetes who were naïve or experienced taking oral antidiabetic agents were randomly assigned to five once-weekly doses of omarigliptin (0.25 mg, 1 mg, 3 mg, 10 mg, or 25 mg) or placebo. The primary efficacy endpoint is the change from baseline in glycated hemoglobin (HbA1c), and the secondary endpoints are 2-hour postprandial plasma glucose (PMG) and fasting plasma glucose (FPG) . The analysis included all patients who received at least one dose of study drug. Subjects who complete the base study are eligible to participate in the 66-week extension study.

Results from the trial showed that once-weekly treatment with ologliptin for 12 weeks resulted in dose-related reductions in glycated hemoglobin, 2-hourblood glucose, and fasting blood glucose. At week 12, the 25 mg dose of ologliptin provided the greatest glycemic benefit. The least squares average reductions in glycated hemoglobin, 2 hoursblood glucose and fasting blood glucose from baseline were -0.72% (-7.8 mmol/mol), -2.5 and -1.3 mmol/L respectively (all P<0.001). The incidence of adverse events was similar across dose groups, with a low incidence of symptomatic hypoglycemia and no effect on body weight. Ologliptin was generally well tolerated throughout the baseline and extension studies.

The original drug Ologliptin is not marketed in the country and is therefore not included in medical insurance. The price of each box of generic Ologliptin drugs currently on the market overseas may be more than more than 1,000 yuan (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.